It is certainly a big step taken on the way to the production of a first vaccine against the coronavirus.
Published, Monday, July 20, in the British medical journal The Lancet, two British vaccines, the other Chinese, generated “a strong immune response” and are well tolerated by patients, a scientific breakthrough that marks this race for the first anti-coronavirus vaccine.
Developed by the University of Oxford in partnership with the Pharmaceutical Group Astrazeneca, the first vaccine generated, according to the AFP agency, the production of immune response antibodies, in a clinical trial on more than 1,000 patients.
The second project, carried out in Wuhan (China) by researchers from several organizations, also led to a “double immune response against the coronavirus in most participants, according to a separate trial of around 500 people”.
Still according to the same source, these two vaccines are in a clinical trial phase, their effectiveness must still be established in a phase 3 trial, on a larger number of participants, before considering their large -scale marketing.
